Aprepitant Anticipation:
This was the first drug to be approved as a Tachykinin antagonist.52Since then this has been tried in numerous clinical trials for numerous indications. There are various trials that have tried the role of aprepitant as an antiemetic drug for the treatment of highly emetogenic conditions like following cancer chemotherapy and some following surgical procedures for PONV. The trial done with aprepitant in HIV infected individuals showed no viral load reduction despite reduction in biological activity.71A few trials were successful but for many trials the information was not available and some were terminated. Aprepitant was tried in germ cell tumours and was found to have a complete remission rate as compared to placebo (NCT00572572). Another study that involved aprepitant in its well-known indication for CINV following cisplatin chemotherapy (NCT00619359). Again, trials involving Aprepitant in PONV and with other drugs like granisetron, dexamethasone, prochlorperazine and palonosetron (NCT00475085 and NCT00819039) showed it to be an effective drug for antiemesis, but still its effect in other indications is still in the line and yet to be established this might become feasible in the near future if research continues to flourish.
Table 3